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Objective: To determine the content of bradykinin (BK) and markers of cartilage degradation and
inﬂammation in the synovial ﬂuid (SF) of patients with knee osteoarthritis (OA), and to evaluate cor-
relations with biomarkers or clinical parameters.
Methods: SFs were obtained from 30 patients with knee OA. Levels of basal and generated BK, cartilage
oligomeric matrix protein (COMP), interleukin (IL) 1, IL-6, IL-8 and matrix metalloprotease (MMP) 1,
MMP-3, MMP-13 and sulfated glycosaminoglycans (GAGs) were measured by enzyme-linked immuno-
sorbent assay (ELISA) or colorimetric assays.
Results: The mean concentration of basal BK (in the presence of peptidase and protease inhibitors to
avoid degradation and de novo formation of BK) was 422 pg/ml (95% conﬁdence interval, CI, 281e563)
whereas that of in vitro generated BK (in the presence of peptidase inhibitors SFs were incubated 60 min
at 37C to measure the potential capability to generate BK) was 3427 pg/ml (2591e4264). The content of
MMP-13, IL-1a, and IL-1b was under assay sensitivity. Basal BK levels positively correlated (Spearman’s
rank correlation) with GAGs (40 mg/ml, 26e54, r ¼ 0.4834, P ¼ 0.0308) and IL-6 (553 pg/ml, 171e935,
r ¼ 0.3946, P ¼ 0.0377) similarly to the generated BK (GAGs, r ¼ 0.4563, P ¼ 0.0431; IL-6, r ¼ 0.5605,
P ¼ 0.0019). Statistical analysis of basal BK and biomarkers was signiﬁcant (P ¼ 0.0483). When applying a
stepwise logistic regression analysis considering biomarkers together with clinical parameters, results
indicated that K/L radiographic OA grade and COMP improved the model (P ¼ 0.0032).
Conclusion: The presence of BK in the knee OA SF and its correlations with cartilage degradation and
inﬂammation markers of OA support its participation in OA pathology.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Inﬂammation is recognized to play a signiﬁcant role in the
different molecular aspects involved in the pathogenesis of osteo-
arthritis (OA), further contributing to the highly catabolic state,
chondrocyte apoptosis, and the resultant progressive degeneration
of articular cartilage1,2.S. Meini, Menarini Ricerche,
055-5680736; Fax: 39-055-
.it (F. Bellucci), smeini@
rini-ricerche.it (P. Cucchi),
izzardo@menarini-ricerche.it
giacoguidelli@hotmail.com
ti7@virgilio.it (A. Fioravanti),
s Research Society International. PKinins are a family of small peptides largely involved in pro-
inﬂammatory mechanisms and pain3. Speciﬁcally, bradykinin (BK,
H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH) and its N-terminal
extended form Lys-BK (known also as kallidin), are formed by the
enzymatic action of plasma and tissue kallikreins, respectively, on
kininogens4. They selectively activate the B2 receptors, belonging to
the seven transmembrane G-protein receptor family, which are
expressed in different cell types, whereas the corresponding pep-
tides lacking the C-terminal arginine are the selective agonists for
the B1 receptor subtype5. Once bound to B2 receptors, BK induces
activation of phospholipase C (PLC) and the following signalings,
involving protein kinase C and phospholipase A2 phosphorylation,
nitric oxide synthase activation, and the subsequent intracellular
downstream signaling5, with the consequent release of inﬂamma-
tory mediators which contribute to cell inﬂammatory responses and
activation/sensitization of afferent nociceptive sensory ﬁbers3,6.ublished by Elsevier Ltd. All rights reserved.
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ceptors in the pathophysiology of OA7. Kinin B2 receptors, but not
B1, have been detected in the synovial lining cells, ﬁbroblasts and
endothelial lining cells of blood vessels from OA patients8, and a
recent report indicates a speciﬁc BK B2 receptor polymorphisms as
associated with the risk and severity of OA9. In a Phase II study
on patients with symptomatic knee OA, the intra-articular injection
of the peptide B2 receptor antagonist icatibant reduced the pain
intensity10. At the present, also a non-peptide B2 receptor antago-
nist fasitibant (previously known as MEN16132) is evaluated
as intra-articular treatment of symptomatic OA (Clinical Trial
NCT01091116 registered).
The content of BK in the knee synovial ﬂuid (SF) has been early
investigated in patients affected by joint diseases including OA, but
results were pooled and not reported according to the different
etiologies11e13. More recently levels of BK have been quantiﬁed in
the SF from knees of rheumatoid arthritis (RA) patients14. Thus
the main goal of the present study was to quantify the BK in the SF
of knee OA patients, and to compare it with the potential capability
of SF to newly generate BK, as an indirect evaluation of kallikrein
and kininogen present in the SF13,14. Then, we sought to evaluate
possible correlation with clinical parameters: radiographic Kellg-
reneLawrence grade, Visual Analogue Scale (VAS) score, and
Lequesne’s algofunctional index. Moreover, because of the growing
interest on the measurements of biomarkers as a mean of diag-
nosing and monitoring OA15e17, molecules derived from cartilage
breakdown, such as cartilage oligomeric matrix protein (COMP)
and sulfated glycosaminoglycans (GAGs) were measured in the
same SF samples, as well as proinﬂammatory mediators, like cy-
tokines (interleukin (IL)-1a, IL-b, IL-6, IL-8) and matrix metal-
loproteases (MMPs, MMP-1, MMP-3, MMP-13), and analyzed for
possible correlation with BK content in SF.
Methods
Patients
SFs were collected from 30 consecutive patients with primary
OA of the knee joint attending the outpatient clinic of the Rheu-
matology Unit, Department of Medicine, Surgery and Neurosci-
ences of the University of Siena. Patients were diagnosed according
the American College of Rheumatology criteria for knee OA18. All
subjects presented swelling and stiffness in the affected knees.
Patients with other diseases among those involving knee joint
were excluded, in particular inﬂammatory arthritis (i.e., RA,
spondyloarthritis, gout and pseudogout), autoimmune disease (i.e.,
connective tissue disorders), septic arthritis, previous knee injury
or intra-articular fracture. Furthermore, subjects with steroid or
hyaluronic acid injections in the affected knee joint within 3
months of recruitment for the study, were not included. Each
subject recruited into this study was evaluated with a thorough
history and physical examination. Height and weight were
measured on the day of the visit to calculate the body mass index
(BMI). Pain severity was assessed on a VAS of 100 mm where
0 represents the absence of pain and 100 is the extreme pain
condition19. Functional impairment was assessed according to the
Lequesne’s algofunctional index (from 0 to 24) given by the point
score determined by a point score deriving from the validated
disease-speciﬁc questionnaire which addresses patients in-
formations on pain or discomfort (ﬁve questions scored on a 0e2
scale, with 0 indicating absent and 2 indicating severe), function
limitation (four questions, 0e2 scale), and maximum distance
walked (one question scored on a 0e6 distance scale, with 0 indi-
cating ability to walk unlimited distances and 6 indicating ability
to walk less than 100 m)20. Plain anteroposterior X-ray wasperformed to evaluate joint destruction; the bilateral weight-
bearing anteroposterior knee radiograph was taken with the pa-
tient standing with toes pointed straight ahead, knees fully
extended, and weight equally distributed on both feet. The X-ray
beam was aimed at the lower pole of the patella and kept parallel
to the joint surface. The grading of radiographs was scored by a
single blinded observer, and OA radiological score was evaluated
with the KellgreneLawrence (KeL) grading scale (as 0 ¼ none,
1 ¼ doubtful, 2 ¼ minimal, 3 ¼ moderate, 4 ¼ severe)21. The study
was approved by the Local Ethical Committee (Azienda Ospeda-
liera Universitaria Senese, on May 20th 2010). Written informed
consent was obtained from all patients.Sample collection
Aspiration of the knee joint effusion was done for the patients
under complete aseptic conditions; SF samples were aspirated via a
lateral infrapatellar approach, using an 18-gauge needle and imme-
diately centrifuged at 4C and 300 g for 15min to remove cell debris.
The supernatant was subdivided in aliquots. Aliquots for the mea-
surement of basal kinin (1 ml) levels contained an equal volume of a
cocktail of proteases (0.4 mg/ml aprotinin, 4 mg/ml soybean trypsin
inhibitor) and kininases inhibitors (10 mM captopril, 10 mM phos-
phoramidon, 60 mM ethylenediaminetetraacetic acid, 6 mM 1,10-
phenanthroline) to prevent formation and breakdown of kinins14.
Aliquots for the measurement of generated kinin levels (1 ml) con-
tained an equal volume of the kininases inhibitors cocktail only and
were incubated at 37C for 60 min14. The remained SF was used for
the measurement of inﬂammatory mediators and cartilage bio-
markers. All collected SFs were treated with hyaluronidase (22.5 U/
ml) at 37C for 30 min to reduce the sample viscosity, and then
stored at 80C.Measurement of basal and generated BK levels
The concentration of basal and generated BK was determined
after peptide extraction by using a human enzyme-linked
immunosorbent assay (ELISA) BK kit in accordance with the
manufacturer instructions (Bachem, CA). The extraction proce-
dure was performed as described in the BK ELISA kit manual
instructions. Brieﬂy, each SF and inhibitors sample was added
with an equal amount (2 ml) of triﬂuoroacetic acid (TFA, 1%,
Buffer A) and centrifuged (15,000 g for 20 min at 4C). Super-
natants were loaded on Sep-Column containing 200 mg of C18
(Peninsula Laboratories, San Carlos, CA) previously washed and
equilibrated by the following buffers: 1 ml of Buffer B (acetoni-
trile 60%, TFA 1%, and distilled water 39%) and 3  3 ml Buffer A.
After SF sample passed through, the Sep-Columns were washed
by using 2  3 ml Buffer A. Extracted peptides were eluted by
adding 3 ml Buffer B and collected in polypropylene tubes.
Extracted samples were frozen in liquid N2, lyophilized and
stored at 20C.
At the moment of the measurement the residues were recon-
stituted in 200 ml of assay buffer. Each sample was assessed in
duplicate and diluted in assay buffer when necessary. BK concen-
tration was corrected by referring to the volume of the collected
sample (1 ml). The minimum detectable level for this assay was
10 pg/ml. This assay can recognize B2 receptor ligands such as BK
and Lys-BK, whereas it does not recognize B1 receptor ligands (i.e.,
[desArg9]-BK and [desArg9]-Lys-BK) (according to data from the
manufacturer and conﬁrming data obtained in our laboratories).
Throughout the manuscript the term BK is used to indicate both B2
receptor peptide ligands: BK and Lys-BK.
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Fig. 1. Correlation of basal and generated BK levels in SF of OA patients. Samples
(n ¼ 28) were extracted as described in Methods and measured by ELISA. Spearman’s
rank correlation coefﬁcient (r) and the resulting P value are inserted.
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The concentration of the total sulfated GAGs was determined by
the quantitative dye-binding method Blyscan assay (Biocolor, UK),
and the minimum detectable level was 10 mg/ml. The concentration
of all the other markers was determined by commercial human
ELISA kits as next described. The product and the assay sensitivity
are indicated in parentheses: COMP (Anamar, Sweden, assay
sensitivity 4 U/L, manufacturer indicated that 1 U/L corresponds to
1 mg/ml, this latter unit has been used throughout the manuscript),
IL-6 (Promokine, Germany, sensitivity 156 pg/ml), IL-8 (Promokine,
assay sensitivity 15.6 pg/ml), IL-1a (Cayman, MI, assay sensitivity
3.9 pg/ml), IL-1b (Cayman, assay sensitivity 1.5 pg/ml), MMP-1
(Abnova, Taoyuan County, Taiwan, assay sensitivity 156 pg/ml),
MMP-3 (Invitrogen, CA, assay sensitivity 32 pg/ml), MMP-13 (Cal-
biochem, CA, assay sensitivity 32 pg/ml). Each sample was assessed
in duplicate and diluted in the appropriate assay buffer when
necessary.
Statistical analysis
Descriptive statistic and further analysis were performed by
using the GraphPad Prism 4.0 software (GraphPad Inc., San Diego,
CA) and the SAS v.9.2 (SAS Institute Inc., Cary, NC, USA). All values in
the text are reported as mean and 95% conﬁdence interval (CI).
Patients characteristics are expressed by median (minimume
maximum) (Table I). The Spearman rank correlation coefﬁcient was
used to examine the relationship among BK, the different markers,
and clinical pain and function parameters, using two-tailed P values
of 0.05 as criteria for statistical signiﬁcance. The non-parametric
KruskaleWallis test was used for the comparison with the KeL
score. The non-parametric Wilcoxon matched pairs t test was used
to compare basal and generated BK levels in the SF.
BK levels were analyzed in function of the other biomarkers
levels, by using an analysis of variance (ANOVA) model. The anal-
ysis was performed considering as dependent variable the values of
basal BK. Furthermore, a stepwise logistic regression analysis was
performed to determine whether basal BK levels in the SF of OA
patients were associated with all the measured biomarkers, de-
mographic parameters (age and BMI) and clinical data (VAS,
Lequesne, and KeL) with a signiﬁcant levels to enter and to stay in
the model of P < 0.5 and 0.3, respectively.
Results
Basal and generated BK contents
BK was assessed in 28 out of 30 SF samples, as two samples
could not be recovered during the peptide extraction procedure. BK
was detected in all the tested SF samples (n ¼ 28). The mean value
of BK (basal) was 422 pg/ml (95% CI 281e563). The BK content inTable I
Characteristics and clinical parameters of the knee OA patients
Male 9 (30%)
Female 21 (70%)
Age 75 (57e89)
BMI 25.70 (20.50e33.90)
KeL score
2 40%
3 53%
4 7%
VAS score 33 (9e63)
Lequesne’s functional index (units) 10.5 (5.5e14.5)
Data (n ¼ 30) are expressed by median (minimumemaximum) or percentage.samples, which were previously incubated at 37C for 60 min
(generated BK) was signiﬁcantly greater (P< 0.0001) than the basal
content: 3427 pg/ml (95% CI, 2591e4264). During this incubation
(in the presence of kininases but not proteases inhibitors, see
Methods) BK is formed by the enzymic action of kallikrein on the
substrate kininogen, thus indicating the potential capability of SF to
generate BK. There was a signiﬁcant positive correlation between
basal and generated kinin levels (r ¼ 0.4384; P ¼ 0.0196, Fig. 1).Biochemical markers
The concentration of biomarkers measured in the SF of OA pa-
tients is reported in Table II. IL-1a and IL-1b could not be detected in
any of the SF samples with the used methods (detection limit 3.9
and 1.5 pg/ml, respectively). MMP-13 was also undetectable
(<32 pg/ml) in 28 samples (Table II), whereas in two SF samples the
MMP-13 content was 1363 and 192 pg/ml; no other differences
(outliers values) in all measured biomarkers could be detected in
the samples from the same two patients. All the other biomarkers
were detected in all the 30 SF samples, except for GAGs that was
assessed in 20 out of 30 SF samples because the collected volume
was not sufﬁcient. Measured concentrations of IL-6, IL-8, MMP-1,
and MMP-3 are described in Table II. Among detected biomarkers
a positive correlation was found between COMP and total sulfated
GAGs levels (Table III, n¼ 20) and also betweenMMP-1 andMMP-3
values (Table III, n ¼ 30).Relationship between BK levels, clinical parameters and other
biomarkers
In the examined group of knee OA patients the Lequesne’s index
of function and the VAS pain score signiﬁcantly correlated (Table I,
Fig. 2). No correlation was found with the KeL score as index of OA
severity. Both basal and generated kinin levels had no signiﬁcantTable II
Levels of biochemical markers detected in the SF from the knee of OA patients
Biomarker Mean (95% CI) n
COMP (mg/ml) 60 (52e68) 30
GAG (mg/ml) 40 (26e54) 20
IL-1a (pg/ml) <3,9 30
IL-1b (pg/ml) <1,5 30
IL-6 (pg/ml) 553 (171e935) 30
IL-8 (pg/ml) 114 (53e175) 30
MMP-1 (ng/ml) 235 (123e347) 30
MMP-3 (ng/ml) 1230 (588e1872) 30
MMP-13 (pg/ml) <32 28
Table III
Spearman’s rank correlation coefﬁcients (r) among biomarkers detected in the knee SF of OA patients
IL-6 IL-8 MMP-1 MMP-3 COMP GAGs
IL-6 1.0000
IL-8 r ¼ 0.0743
P ¼ 0.6965
1.0000
MMP-1 r ¼ 0.3214
P ¼ 0.0953
r ¼ 0.1662
P ¼ 0.3802
1.0000
MMP-3 r ¼ 0.3364
P ¼ 0.0691
r ¼ 0.1973
P ¼ 0.2960
r ¼ 0.8789
P < 0.0001
1.0000
COMP r ¼ 0.0376
P ¼ 0.8434
r ¼ 0.1227
P ¼ 0.5183
r ¼ 0.2007
P ¼ 0.2876
r ¼ 0.2621
P ¼ 0.1617
1.0000
GAGs r ¼ 0.1918
P ¼ 0.4179
r ¼ 0.1601
P ¼ 0.5002
r ¼ 0.0471
P ¼ 0.8437
r ¼ 0.0323
P ¼ 0.8923
r ¼ 0.7587
P < 0.0001
1.0000
n ¼ 30, correlations vs GAGs n ¼ 20.
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activity: radiographic KeL grade (basal BK P¼ 0.6211, generated BK
P ¼ 0.3596), VAS score (basal: r ¼ 0.3785, P ¼ 0.0470, n ¼ 28;
generated: r ¼ 0.1215, P ¼ 0.5379, n ¼ 28), and Lequesne’s algo-
functional index (basal: r¼0.1123, P¼ 0.5695, n¼ 28; generated:
r ¼ 0.1186, P ¼ 0.5479, n ¼ 28).
Basal and generated BK levels correlated positively with total
sulfated GAGs levels [Fig. 3(A) and (B)] andwith IL-6 contents in the
SF sample [Fig. 3(C) and (D)]. Amongst all the investigated bio-
markers only the COMP concentration was found to positively
correlate with VAS [Fig. 4(A)] and Lequesne’s algofunctional index
[Fig. 4(B)].
The ANOVA performed with basal BK as dependent variable and
all the other biomarkers values indicated a signiﬁcant interaction
(P ¼ 0.0483). When the stepwise logistic regression analysis was
performed, even considering demographic and disease parameters,
the best model obtained was BK ¼ KeL þ IL-6 þ GAGs þ COMP
(P ¼ 0.0032).
Discussion
We described the levels of BK (and its extended N-terminal form
Lys-BK) in the SF of knee OA patients. As mentioned in the intro-
duction, although the presence of BK into the SF of knee OA patients
had been demonstrated previously, speciﬁc values of content were
not given11e13. In absolute terms the quantity of BK we found in
knee OA SF (422 pg/ml) appears lower than that found in RA pa-
tients (5.7 ng/ml, 0.43e26.17)14, which is consistent with the
generally different levels of inﬂammatory markers found in these
two forms of arthritis: lower in OA and higher in RA22e24. The fact
that OA SF can generate a further amount of BK after an appropriate
incubation (at 37C, and in the presence of kininase inhibitors butLequesne's index
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Fig. 2. Correlation between the VAS pain score and the Lequesne’s algofunctional in-
dex in OA patients (n ¼ 30). Spearman’s rank correlation coefﬁcient (r) and the
resulting P value are inserted.in the absence of protease inhibitors) indicates the presence of both
kininogens, the precursors macromolecules, and kallikreins, the
enzyme that by acting on kininogens form BK. Again the capacity of
OA SF to newly generate BK (about 8-fold vs the basal BK) is
somewhat lower than that observed in RA SF (20-fold)14, in
agreement with the greater kallikrein enzyme activity evidenced in
RA compared with OA SF25,26. Contrary to RA SF14, present data
indicate a positive correlation between basal BK levels and the
capacity for BK generation in OA SF, suggesting a proportional
presence of both kininogens and kallikreins in the OA SF.
BK B2 receptors are present on human chondrocytes and syno-
vial cells7 and once activated by BK these cells can release IL-6, IL-8,
and MMP-327e30, or interact with IL-1b signaling to synergistically
increase cyclooxygenase 2 expression and the consequent prosta-
noid production31. In OA SF we found levels of IL-6, IL-8, MMP-1,
and MMP-3 comparable to those assessed in previous compara-
tive analyses22,23,32e34. On the other hand, MMP-13 could be
quantiﬁed only in two out of 30 OA SF examined, in line with
previously different reports33,35,36. Moreover, neither IL-1a nor
IL-1b could be detected in the examined SF, thus conﬁrming the
quite low concentration of these cytokines in OA23,37e39.
Among BK and examined cytokines and MMPs, we found that
BK positively and signiﬁcantly correlated with IL-6, and that this
signiﬁcance was greater if other parameters were considered in the
analysis, amongst which the KeL radiographic score. These results
agree with those studies that measured higher circulating levels of
IL-6 associated with an increased radiographic knee OA severity40
and inﬂammation37. On the other hand it has been reported that
IL-6 content in OA SF is increased in the early stages of OA pro-
gression and correlates with joint function41. IL-6 is also likely to
participate in cartilage catabolism and pain mechanism as it can
increase the expression of MMPs and aggrecanases42, besides to
induce sensitization of afferent nociceptive ﬁbers in preclinical
models43,44, similarly to BK6.
In agreement with previous reports on OA SF biomarkers
we found a positive correlation between MMP-1 and MMP-3
levels45e47, but we could not demonstrate any correlation with
the BK content.
Moreover, in this study we show that a positive correlation
occurs between BK and sulfated GAGs, but not COMP. COMP is an
important component of hyaline cartilage, and as indicator of its
metabolism is largely recognized as a predictive biomarker of knee
OA progression48,49. In the present study, levels of COMP were
comparable to those previously reported in SF from OA pa-
tients48,50e52. Although COMP did not correlate with the measured
levels of BK, it contributed to reinforce the interaction modeling, as
above discussed for the KeL radiographic score. This result is in line
with the previous observations that COMP levels are higher in SFs
from OA patients with higher radiographic KeL grades50,52,53.
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Fig. 3. Correlation of basal and generated BK levels with GAGs (A-B, n ¼ 20) and IL-6 (C-D, n ¼ 28) in OA knee SF. Spearman’s rank correlation coefﬁcient (r) and the resulting P value
are inserted.
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severity (KeL score), we found a signiﬁcant correlation with VAS
score and Lequesne’s index. Contrasting data have been reported
about the correlation between synovial and serum levels of COMP
and clinical/radiological features in patients with knee OA52e54.
Senolt and coworkers53 did not observe any signiﬁcant correlation
between radiological status of the disease and synovial and serumVAS
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Fig. 4. Correlation of COMP, detected in OA SF, with the pain score (VAS) (A) and with
the functional index score (Lequesne’s index) (B) (n ¼ 30). Spearman’s rank correlation
coefﬁcient (r) and the resulting P value are inserted.COMP levels; whereas El-Arman and coworkers52 referred a posi-
tive correlation between COMP and radiological stage but no with
clinical parameters. These conﬂicting results could be due to the
difference in patients selection or the fact that radiological abnor-
malities may represent the normal ageing process of the cartilage,
while pain is the result of different origin (i.e., synovial membrane,
subchondral bone).
Interestingly we found that levels of COMP and GAGs positively
correlated, thus conﬁrming a strict relation between cartilage
turnover and degradation in OA SF55. GAGs are products derived
from degradation of proteoglycans, one of the major components of
the extracellular matrix of articular cartilage56. Sulfated GAGs, as
measured in this study, include chondroitin sulfate, dermatan sul-
fate, and keratan sulfate, that all reﬂect cartilage breakdown55,57,58.
However, GAGs have been also related to the presence of inﬂam-
matory cells in SF of patients with knee OA, indicating a relation-
ship between matrix turnover and inﬂammation in this disease59.
In the present study the signiﬁcant positive correlations between
levels of BK, in this case both basal and generated, and those of
sulfated GAGs again link inﬂammation and cartilage breakdown.
Although present data indicate a relationship between cartilage
breakdown in OA and BK, no direct evidence have been provided so
far for a direct involvement of BK in cartilage catabolism mecha-
nisms, apart the capability to induce MMP-3 release from human
chondrocytes29, and further speciﬁc investigations are needed to
clarify any implication of BK in degradative processes.
BK detection in the SF of OA patients, together with its rela-
tionship with markers of cartilage destruction and synovial
inﬂammation, indicate this peptide as an endogenous pro-
inﬂammatory molecule that participates in the mechanisms
related to knee OA, and support the potential use of BK B2 receptor
antagonists as symptomatic therapy for this disease.
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